Pain
Conditions
Keywords
lidocaine implantation ICD
Brief summary
The use of lidocaine, as an anesthetic drug, during implantation of an implantable cardioverter-defibrillator(ICD)will not result in a clinically significant alteration of the defibrillation threshold during ICD placement.
Detailed description
Summary: The purpose is to observe the incidence of successful defibrillation on the first attempt during implantation of an implantable cardioverter-defibrillator (ICD) among patients who receive a standard dose of intravenous lidocaine (for attenuation of pain associated with propofol injection) versus patients who do not receive an intravenous lidocaine dose. During implantation of an ICD, defibrillation threshold (DFT) testing is performed. DFT is calibrated as the lowest energy delivered by the ICD that will successfully terminate malignant arrhythmia. Lidocaine, a routine anesthetic agent, is also identified as an antiarrhythmic drug. Experimentally, lidocaine has been shown to increase thresholds during DFT' testing due to the drugs dual effect. The rationale behind this project is that the lidocaine may yield falsely elevated DFT, resulting in higher calibration of the ICD device. This alteration can affect ICD battery and overall ICD life. Comparisons between study groups may elucidate effects of IV lidocaine on DFT.
Interventions
DRUGlidocaine
A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
DRUGPlacebo
A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
Sponsors
Drexel University College of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Any person referred to the Hahnemann University Hospital Electrophysiology Laboratory for a clinically indicated ICD implant
Exclusion criteria
* Any person under the age of 18 years * Inability to give an informed consent * Allergy to lidocaine * Receiving lidocaine treatment for pain or arrhythmia * Contraindication for DFT testing * Not consenting for DFT testing * Receiving energy other than 10-12.5 joules as initial DFT test * Implant of ICD on the right side * DFT not planned to be performed during ICD implant * Epicardial placement of ICD leads * Use of single coil ICD lead * Subpectoral ICD implantation * Cephalic cutdown used for central venous access * Require more than 3mg/kg of 1% SQ lidocaine for local anesthesia * Pregnant women or prisoners
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of successful defibrillation on first attempt with 10-12 joules. | Through study completion but no longer than 1 year | These patients will receive a standard dose of intravenous lidocaine (for attenuation of pain associated with propofol injection) versus patients who do not receive an intravenous lidocaine dose. Outcome is to have a success defibrillation within the first attempt. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of failure to defibrillate at higher energy levels. | Through study completion but no longer than 1 year | This outcome occurs when research team fails to defibrillate on any attempt. |
| Defibrillation threshold (DFT) for subjects who fail to defibrillate at the initial 10-12 joules. | Through study completion but no longer than 1 year | This outcome occurs when research team fails to defibrillate on first attempt. |
Countries
United States
Outcome results
None listed